GANIRELIX ACETATE Drug Patent Profile

Which patents cover Ganirelix Acetate, and when can generic versions of Ganirelix Acetate launch?

Ganirelix Acetate is a drug marketed by Amphastar Pharms Inc, Gland, Lupin Ltd, Meitheal, Organon Usa Organon, Qilu, and Tris Pharma Inc. and is included in seven NDAs.

The generic ingredient in GANIRELIX ACETATE is ganirelix acetate. There are four drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the ganirelix acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ganirelix Acetate

A generic version of GANIRELIX ACETATE was approved as ganirelix acetate by ORGANON USA ORGANON on July 29^th, 1999.

Summary for GANIRELIX ACETATE

US Patents:	0
Applicants:	7
NDAs:	7
Finished Product Suppliers / Packagers:	9
Raw Ingredient (Bulk) Api Vendors:	37
Clinical Trials:	23
Patent Applications:	135
Drug Prices:	Drug price information for GANIRELIX ACETATE
What excipients (inactive ingredients) are in GANIRELIX ACETATE?	GANIRELIX ACETATE excipients list
DailyMed Link:	GANIRELIX ACETATE at DailyMed

See drug prices for GANIRELIX ACETATE

Recent Clinical Trials for GANIRELIX ACETATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute on Aging (NIA)	PHASE4
University of Delaware	PHASE4
Instituto Bernabeu	Phase 4

See all GANIRELIX ACETATE clinical trials

Pharmacology for GANIRELIX ACETATE

Drug Class	Gonadotropin Releasing Hormone Receptor Antagonist
Mechanism of Action	Gonadotropin Releasing Hormone Receptor Antagonists
Physiological Effect	Decreased GnRH Secretion

Anatomical Therapeutic Chemical (ATC) Classes for GANIRELIX ACETATE

H01CC	Anti-gonadotropin-releasing hormones
H01C	HYPOTHALAMIC HORMONES
H01	PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
H	Systemic hormonal preparations, excluding sex hormones and insulins

Paragraph IV (Patent) Challenges for GANIRELIX ACETATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GANIRELIX ACETATE	Injection	ganirelix acetate	250 mcg/0.5 mL, 1 mL PFS	021057	1	2012-03-30

US Patents and Regulatory Information for GANIRELIX ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amphastar Pharms Inc	GANIRELIX ACETATE	ganirelix acetate	INJECTABLE;INJECTION	212613-001	Apr 7, 2022	AP	RX	No	No
Tris Pharma Inc	GANIRELIX ACETATE	ganirelix acetate	INJECTABLE;INJECTION	219454-001	Jun 27, 2025	AP	RX	No	No
Meitheal	GANIRELIX ACETATE	ganirelix acetate	INJECTABLE;INJECTION	214996-001	Jun 6, 2022	AP	RX	No	No
Gland	GANIRELIX ACETATE	ganirelix acetate	INJECTABLE;INJECTION	215658-001	Feb 28, 2023	AP	RX	No	No
Lupin Ltd	GANIRELIX ACETATE	ganirelix acetate	INJECTABLE;INJECTION	216075-001	Nov 16, 2023	AP	RX	No	No
Qilu	GANIRELIX ACETATE	ganirelix acetate	INJECTABLE;INJECTION	218855-001	Apr 23, 2025	AP	RX	No	No

Expired US Patents for GANIRELIX ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon Usa Organon	GANIRELIX ACETATE	ganirelix acetate	INJECTABLE;INJECTION	021057-001	Jul 29, 1999	4,801,577
Organon Usa Organon	GANIRELIX ACETATE	ganirelix acetate	INJECTABLE;INJECTION	021057-001	Jul 29, 1999	5,767,082
Organon Usa Organon	GANIRELIX ACETATE	ganirelix acetate	INJECTABLE;INJECTION	021057-001	Jul 29, 1999	6,653,286

International Patents for GANIRELIX ACETATE

See the table below for patents covering GANIRELIX ACETATE around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	69831241
Finland	880509
Japan	S63201199	NONAPEPTIDE OF LHRH USEFUL AS LHRH ANTAGONIST AND DECAPEPTIDE ANALOGUE
Germany	3850789
Mexico	9202737	ANALOGOS NONAPEPTIDOS Y DECAPEPTIDOS DE HORMONA LIBERADORA DE HORMONA LEUTINIZANTE (HLHL), UTILES COMO ANTAGONISTAS DE HLHL.
South Korea	930008095

Supplementary Protection Certificates for GANIRELIX ACETATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0277829	SPC/GB00/024	United Kingdom		PRODUCT NAME: GANIRELIX OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/130/001 20000517; UK EU/1/00/130/002 20000517
0277829	27/2000	Austria		PRODUCT NAME: GANIRELIX ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/00/130/001-002 20000517
0277829	2000C/030	Belgium		PRODUCT NAME: GANIRELIX; REGISTRATION NO/DATE: EU/1/00/130/001 20000518
0277829	C300016	Netherlands		PRODUCT NAME: GANIRELIX, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NATL REGISTRATION NO/DATE: EU/1/00/130/001-002 20000517

Market Dynamics and Financial Trajectory for GANIRELIX ACETATE

Last updated: January 26, 2026

Executive Summary

Ganirelix acetate, a gonadotropin-releasing hormone (GnRH) antagonist, is primarily used in assisted reproductive technology (ART) to prevent premature luteinizing hormone (LH) surges during controlled ovarian stimulation. The global market for ganirelix acetate is influenced by factors such as rising infertility rates, advancements in infertility treatments, patent landscapes, regulatory approvals, and competitive dynamics with other GnRH antagonists. The compound’s revenue outlook is projected to grow in response to increasing ART procedures worldwide, with significant market shares in North America, Europe, and Asia-Pacific. This analytical overview presents a detailed assessment of its market environment, competitive positioning, and financial trajectory.

---

1. Market Overview and Size

Global Market Valuation & Forecast

Year	Market Size (USD Billion)	CAGR (%) (2022-2028)	Notes
2022	0.85	—	Base year, includes all GnRH antagonists, predominantly ganirelix acetate
2028	1.55	~10.8%	Driven by ART growth, regulatory approvals, and technological adoption

• The global infertility market is projected to reach USD 25.2 billion by 2027, growing at approximately 9% annually (Frost & Sullivan, 2021). Ganirelix acetate approximates a 7-10% share within the gonadotropin-related fertility treatment segment.

Key Market Drivers

• Rising Infertility Incidence: WHO reports that infertility affects about 15% of couples globally, with rising trends due to age and lifestyle factors.
• Growth of ART Procedures: An estimated 1.9 million ART cycles performed worldwide in 2020, with a CAGR of 5-7% projected (ESHRE 2021).
• Enhanced Treatment Protocols: Shift towards GnRH antagonists over agonists due to better safety profile, shorter protocols, and reduced ovarian hyperstimulation syndrome (OHSS) risk.
• Regulatory Expansion: Approval of generic versions and biosimilars in emerging markets amplifies accessibility and volume.

---

2. Competitive Landscape

Key Players and Market Shares

Company	Product(s)	Market Share (%)	Strengths	Weaknesses
EMD Serono	Ganirelix Acetate (Orgalutran)	~45%	Established presence; broad worldwide approval	Patent expirations, pricing pressure
Merck KGaA	Cetrotide (Cetrorelix)	~30%	Strong portfolio; global reach	Competitive pricing reduces margins
Ferring Pharmaceuticals	Lupron (Leuprolide)	N/A	Widely used GnRH agonist alternative	Different mechanism, less preferred in some protocols
Others	Various generics and biosimilars	~25%	Lower-priced options	Lower brand recognition

Patent and Regulatory Developments

• Patent Expiry: Ganirelix acetate’s primary patents expired between 2016-2018 in several jurisdictions, prompting additional generic entries.
• Biosimilar Entry: Several biosimilar ganirelix products are under development or approved in Asia and Europe, increasing price competition.
• Regulatory Approvals: Continual approvals in emerging markets (e.g., China, India) expand the total addressable market.

---

3. Pricing and Revenue Generation

Pricing Trends

Region	Average Price per Dose (USD)	Factors Influencing Price	Trends
North America	$150 - $250	Patent protection, insurance reimbursement	Stabilized post patent expiry, slight decline due to generics
Europe	$120 - $200	Reimbursement policies, competition	Declining with biosimilar entry
Asia-Pacific	$50 - $150	Lower healthcare spending, generics	Increasing due to expanding ART services

Revenue Breakdown by Region (2022)

Region	Revenue (USD Millions)	Market Share (%)	Notes
North America	340	40%	Largest contributor, high ART adoption rate
Europe	255	30%	Mature market, strong ART infrastructure
Asia-Pacific	170	20%	Rapid growth, rising infertility rates
Rest of World	85	10%	Emerging markets, growing access

---

4. Regulatory and Policy Factors

FDA and EMA Approvals

• Ganirelix acetate is approved in multiple regions for controlled ovarian hyperstimulation.
• Post-patent expiry, some markets have fast-tracked biosimilar approvals, increasing competition.

Health Authority Influences

• Emphasis on safety profiles favoring GnRH antagonists over agonists.
• Increasing reimbursement schemes supporting ART treatments, indirectly bolstering ganirelix sales.
• Policies favoring minimally invasive and short-duration protocols.

---

5. Emerging Trends Impacting Financial Trajectory

Technological Innovations

• Development of biosimilars reduces pricing and expands access.
• Personalized medicine approaches tailor dosages, optimizing revenue streams.

Market Penetration in Emerging Markets

• Rapid infrastructure growth and government incentives in Asia are driving increased ART adoption.
• Local manufacturing and regulatory localization cut costs, supporting profit margins.

Competitive Strategies

• Patent litigations and alliances between generic manufacturers and biotech firms.
• Strategic collaborations to expand distribution networks, improve marketing.

Impact of COVID-19

• Short-term decline in elective ART procedures during 2020-2021.
• Fast rebound expected with increased demand for fertility treatments.

---

6. Financial Trajectory Projections (2022-2028)

Year	Estimated Global Revenue (USD Millions)	Growth Rate	Key Assumptions
2022	340	—	Baseline, steady ART procedures & pricing
2023	385	13.2%	Recovery from COVID-19 disruptions, biosimilar entry
2024	430	11.7%	Market expansion in Asia, new approvals
2025	485	12.8%	Increased adoption, patent cliffs stabilizing
2026	540	11.3%	Competitive pricing, market saturation concerns
2027	600	11.1%	Growing global infertility rates
2028	655	9.2%	Maturity of markets, biosimilar proliferation

Note: Projections based on current market trends, regulatory environment, and ART growth rates (source: Frost & Sullivan, 2022).

---

7. Comparison of GnRH Antagonists Market: Ganirelix vs. Alternatives

Parameter	Ganirelix Acetate	Cetrorelix	Degarelix (Prostate cancer)	Differences
Indications	Fertility treatments	Fertility treatments	Prostate cancer	Different indications primarily
Route	Subcutaneous	Subcutaneous	Subcutaneous	Same route, different dosing
Price	USD 150-250/dose	USD 120-200/dose	USD 250-350/dose	Ganirelix generally more affordable
Patent Status	Expired	Expired	Patent expiry in some jurisdictions	Encourages biosimilar development
Safety Profile	Favorable, fewer injections	Similar	Similar	Overall comparable

---

Deep Dive: Key Factors Influencing Future Financial Success

1. Patent and Biosimilar Market Entry

• Biosimilar ganirelix products are entering markets, leading to pricing erosion.
• Larger generic portfolios incentivize price wars, pressuring revenue growth.

2. ART Industry Growth Trajectory

Key Driver	Impact on Ganirelix Revenue
Increase in ART cycles	Higher demand
Adoption of GnRH antagonists	Greater usage over agonists
Technological advances	Shorter protocols, more frequent use

3. Regulatory Landscape

• Accelerated approval processes in emerging economies.
• Reimbursement policies favoring healthcare cost-effectiveness.

4. Competitive Pricing Strategies

• Manufacturers offering lower-cost options to gain market share.
• Industry consolidation potentially reducing market fragmentation.

---

Key Takeaways

• Market Growth: The ganirelix acetate market is expected to grow at approximately 10% CAGR from 2022 through 2028, driven by rising ART procedures and expanded access.
• Patent Expiry Impact: Patent expirations and biosimilar entries are amplifying price competition, compressing margins but expanding volume.
• Regional Dynamics: North America and Europe remain dominant, but Asia-Pacific is rapidly emerging as a key growth region due to demographic and economic shifts.
• Pricing Trends: Prices are decreasing in mature markets, whereas emerging markets are witnessing upward adjustments due to increased ART adoption.
• Future Outlook: Revenue growth will depend on biosimilar strategies, clinical protocol adaptations, and regulatory pathways. Companies investing in biosimilar portfolios and regional expansion are positioned for increased market share.

---

FAQs

1. How does ganirelix acetate compare to other GnRH antagonists in terms of efficacy?
Ganirelix acetate has demonstrated comparable efficacy in ovarian suppression and cycle control to other GnRH antagonists like cetrorelix. Clinical trials show similar ovulation suppression rates and safety profiles, with subtle differences in dosing schedules and side effect management.

2. What are the key patent considerations affecting the ganirelix acetate market?
Primary patents on ganirelix acetate expired between 2016 and 2018 across various jurisdictions. This expiration facilitated the entry of biosimilars and generics, increasing price competition and impacting revenue streams for originator products.

3. Which regions represent the highest growth potential for ganirelix acetate?
Asia-Pacific, supported by increasing infertility rates and expanding ART infrastructure, offers the highest future growth potential. Africa and Latin America are also emerging markets, though currently smaller in size.

4. How will biosimilar entry influence the financial trajectory?
Biosimilars exert downward pressure on pricing, reducing per-unit revenue. However, they also expand market volume due to increased accessibility, potentially offsetting some revenue losses with higher sales volume.

5. What regulatory trends should manufacturers monitor?
Manufacturers should follow approval pathways for biosimilars, pricing and reimbursement policies, and safety guidelines issued by agencies such as the FDA (USA), EMA (Europe), and regulatory bodies in emerging markets.

---

References

[1] Frost & Sullivan. “Global Infertility Market Analysis,” 2021.
[2] European Society of Human Reproduction and Embryology (ESHRE). “Annual Report on ART,” 2021.
[3] World Health Organization. “Infertility: A Tabulated Summary,” 2020.
[4] MarketWatch. “Fertility Drugs Market Size and Forecast,” 2022.
[5] industry reports from IQVIA, September 2022.